| Logo | Name | Σ | Employees | ||
|---|---|---|---|---|---|
 | Casdin Capital, LLC Life Science Investments Casdin Capital, LLC is a New York-based research investment firm focused on the innovations in molecular medicine currently reshaping Life Sciences and healthcare. Founded in 2011, and with an eye to long-term returns and disruptive technologies, Casdin Capital is an expert working with experts, benefiting from its position at the crossroads of the science and investment communities. As trusted investor-partners in both private and public companies, we collaborate with industry leaders to fuel their visions, adding energy, insight, and experience to our over $2.4 billion under management. As we push into new markets and new developments, we … Type: | 6 | 2 | 0 | 48 |
 |  Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory Type: | 1 | 0 | 0 | 20 |
 | American Chemical Society Improving all people’s lives through the transforming power of chemistry. The American Chemical Society is a congressionally chartered independent membership organization that represents professionals at all degree levels and in all fields of the chemical sciences. With more than 150,000 members, ACS is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization, ACS is at the forefront of the evolving chemistry enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe. ACS is dynamic and visionary, committed to “Improving all people’s lives through the … Type: | 3 | 2 | 0 | 2,192 |
 | The Carlyle Group Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $426 billion of assets under management, Carlyle’s purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 28 offices across four continents. Type: | 8 | 7 | 0 | 2,559 |
 | T. Rowe Price T. Rowe Price is a premiere global asset management organization, actively investing in opportunities to help people thrive in an evolving world. Headquartered in Baltimore, Maryland, we provide a broad range of investment solutions across equity, fixed income, and multi-asset capabilities for clients around the world—from individuals to advisors to institutions to retirement plan sponsors. Our active, independent investing approach has guided how we do business for more than 85 years. Our professionals have diverse perspectives, but are united behind a commitment to rigorous research. They collaborate to identify market risks and opportunities that can give clients sharper insights and … Type: | 1 | 1 | 0 | 8,681 |
 | Parkinson's UK We’ll find a cure. Together. Powered by people. Funded by you. Improving life for everyone affected by Parkinson’s. Your mum, colleague or friend. Anyone can get Parkinson’s, young or old. Every hour, two more people are diagnosed. Unlocking new treatments means delving into the causes of Parkinson’s. That’s why we fund the Parkinson's UK Brain Bank – the world's only brain bank dedicated to Parkinson's research. Over 10,000 people have donated their brains to help scientists around the world to unravel the mysteries of the condition and develop better treatments. The largest charitable funder of Parkinson’s research in Europe, we’re … Type: | 1 | 0 | 0 | 586 |
 | Longwood Fund Longwood creates and invests in science-based companies that develop novel solutions for important medical problems Longwood creates and invests in science-based companies that develop novel solutions for important medical problems. Healthcare and Biotech and entrepreneurialism Type: | 4 | 1 | 0 | 19 |
 | Milano Finanza [Automatic translation follows] The best of economic-financial information, at your disposal, always. MF-Milano Finanza is the national financial and economic newspaper, with the primacy of information on the stock market, economy, investments and markets. A direct line to Piazza Affari and the main world stock exchanges. With dedicated sections: Online Trading, Technical Analysis, ETF, Covered Warrants, Private Equity, Shipping & Logistics and on Saturdays with Milano Finanza important insights into the world of managed savings, securities and real estate investment. The correctness, truthfulness and authoritativeness of the newspaper are recognized by the target and by professionals both at a national … Type: | 4 | 4 | 0 | 282 |
 | SafeHeal Reshaping RecoveryTM Established in 2015 and based in France, SafeHealTM is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal’s premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy. medical device Type: | 2 | 1 | 0 | 18 |
 |  Inventiva Pharma A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc Type: | 1 | 1 | 0 | 117 |
 | LimFlow SA Providing minimally-invasive options for the treatment of end-stage chronic limb-threatening ischemia (CLTI) LimFlow SA, part of Inari Medical, Inc., is a leading provider of medical technology that provides new hope to patients suffering from the most severe form of peripheral artery disease, Chronic Limb-Threatening Ischemia (CLTI), and who are facing the prospect of amputation. LimFlow is revolutionizing healthcare by offering a breakthrough solution for end-stage CLTI patients when traditional treatments fall short. Using an innovative percutaneous procedure, the LimFlow System reinvents anatomy to restore blood flow to the ischemic foot, which aims to alleviate pain, foster wound healing, reduce amputations … Type: | 1 | 1 | 0 | 39 |
 | Frst We are the first believers Frst is a Day One venture firm focused on supporting a new generation of French entrepreneurs with global ambitions. €200m+ AUMA invested in 50+ companies to date. Full portfolio on frst.vc Type: | 6 | 5 | 0 | 6 |
 | ICREA - Institució Catalana de Recerca i Estudis Avançats The need to know ICREA, Catalan Institution for Research and Advanced Studies, is a foundation supported by the Catalan Government and guided by a Board of Trustees. ICREA was created in response to the need to seek new hiring formulas that would make it possible to compete with other research systems on a similar footing by focusing on hiring only the most talented and extraordinary scientists and academics. ICREA is an institution without walls. It works hand in hand with Catalan universities and research centres to integrate ICREA research professors in the Catalan research system. ICREA offers permanent, tenured positions … Type: | 1 | 1 | 0 | 59 |
 | ARCH Venture Partners We are contrarian. We are bold. We are imaginative risk takers. Early stage venture firm focused on life science discoveries to prevent, detect and cure disease. Type: | 2 | 2 | 0 | 62 |
 | Artios Taking control of the DNA Damage Response (DDR) Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. … Type: | 7 | 3 | 0 | 113 |
 | Inspirna, Inc. Converting cancer to a manageable, chronic condition Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE … Type: | 2 | 2 | 0 | 33 |
 | Calliditas Therapeutics Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the lives of patients. Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products. Type: | 5 | 2 | 0 | 228 |
 | Redmile Group Redmile Group is a company based out of San Francisco. Type: | 2 | 2 | 0 | 55 |
 | Gradient Denervation Technologies Transforming the treatment of pulmonary hypertension A solution for patients suffering from heart failure with pulmonary hypertension. Type: | 1 | 1 | 0 | 13 |
 | Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and … Type: | 15 | 14 | 0 | 67,800 |
 | Noema Pharma Developing therapies to restore functioning in patients with orphan conditions of the brain and nervous system. Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. CNS | 1 | 1 | 0 | 32 |
 | Janus Henderson Investors We’re a global asset manager dedicated to investing in a #BrighterFutureTogether for our clients. Janus Henderson’s mission is to help clients define and achieve superior financial outcomes through differentiated insights, disciplined investments and world-class service. We’re dedicated to investing in a brighter future together. Formed in 2017 from the merger between Janus Capital Group and Henderson Global Investors, we have over 89 years’ experience in investing, underpinned by a culture deep rooted in research. With over 340 investment professionals worldwide, who meet regularly to share insights, we’re able to offer a world-class service providing tailored solutions and the personal touch … Type: | 3 | 3 | 0 | 2,938 |
 | Life Extension The Science of a Healthier LifeTM Life Extension® is the health solutions expert that is translating scientific research into everyday insights for people wanting to live their healthiest lives. For almost 40 years, Life Extension® has pursued innovative advances in health, conducting rigorous clinical trials and setting some of the most demanding standards in the industry to offer a full range of quality vitamins and nutritional supplements and blood-testing services. Life Extension’s Wellness Specialists provide personalized counsel to help customers choose the right products for optimal health, nutrition and personal care. Type: | 1 | 1 | 0 | 442 |
 | Kymab Ltd Kymab, a Sanofi company, based in Cambridge UK, is working to provide novel solutions in drug and vaccine development. Kymab, a Sanofi company, is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab’s platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with … Type: | 1 | 1 | 0 | 49 |
 | Abzena Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, … Type: | 6 | 0 | 0 | 446 |
 | deepc Increasing diagnostic quality through the collaboration of medical professionals and AI. deepc is a pioneering company in the realm of Radiology AI, poised to democratize access to health at scale. At the heart of our mission is ourproduct deepcOS®, an unrivaled cloud-native Radiology AI platform. With a vendor-agnostic approach, deepcOS® boasts an expansive repository of cutting-edge AI applications. This groundbreaking platform empowers radiologists to seamlessly include AI insights into their clinical workflows, ushering in a new era of patient care excellence and elevated diagnostic precision. Visit our website now or simply email us at contact@deepc.ai Digital Health, Deep Learning, Machine … Type: | 1 | 1 | 0 | 74 |
 | Tenpoint Therapeutics Ltd Vision-restoring engineered cell-based therapeutics & in vivo reprogramming. Tenpoint Therapeutics is a vision-restoring engineered cell-based therapeutics company. We are embracing a new opportunity to fundamentally reshape the future for people with ocular diseases. We have an ambitious goal with global impact. Type: | 2 | 2 | 0 | 27 |
 | Wellington Management Trusted adviser to investors worldwide For almost 100 years, we have chosen to do things differently, including the way we structure our ownership model, organization, and investment platform. Critically, we know that the best investment ideas are found when a diverse workforce is encouraged to bring forward unique perspectives. Wellington Management is one of the world’s largest independent investment management firms, serving as a trusted adviser to over 2,400 clients in more than 60 countries. We manage more than US$1 trillion for pensions, endowments and foundations, insurers, family offices, fund sponsors, global wealth managers, and other clients. As a private … Type: | 3 | 3 | 0 | 3,616 |
 | Pi-Cardia Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of Aortic Stenosis. The company's proprietary technology is based on delivering mechanical impact for creating scoring lines in valve calcification, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve. Medical Device, Aortic Stenosis, Precautions Catheter-System, and Cardiovascular Type: | 1 | 1 | 0 | 58 |
 | Cure51 From Cancer Survivors to new drugs The first worldwide clinical and molecular database of exceptional survivors leading the path to new therapies against cancer. Type: | 2 | 1 | 0 | 15 |
 | Pixium Vision S.A. Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons ! One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission … Type: | 7 | 5 | 1 | 47 |
 | Innogest Capital Investors in companies that make the difference, partner of entrepreneurial visionaries We are investors in companies that make the difference. We trust in great entrepreneurs, we partner with hard-working visionaries. Innogest is a Venture Capital firm focused on seed and early stage ventures, with more than € 200 milion of capital under management. We have over 100 years of cumulative professional experience in the digital and the healthcare fields. Innogest invests in high potential companies through a direct share in their equity and pays special attention to market potential and size. Innogest leverages its extensive network of contacts, working alongside … Tags: H2020 Type: | 4 | 0 | 1 | 16 |
 | Bicycle Therapeutics Bicycle Precision Guided Therapeutics. Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTCTM) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICATM targeting Nectin-4 and agonizing CD137, … Type: | 6 | 2 | 1 | 274 |
 | Wellcome Sanger Institute The Wellcome Sanger Institute is a world leading genomics research centre. The Wellcome Sanger Institute is a world leader in genomics research. We generate and analyse data at a scale not easily possible elsewhere. We apply and explore genomic technologies to advance the understanding of biology and improve health. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve … Type: | 4 | 3 | 1 | 1,394 |
 | Shockwave Medical Making waves for underserved patients with cardiovascular disease via novel technologies. ⚡🌊 Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with … Type: | 2 | 2 | 1 | 1,123 |
 | BRAIN Biotech AG Developing a biobased future is our passion. Industrial biotechnology is our business. BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in … Type: | 3 | 1 | 1 | 186 |
 | May Health We are bringing a modern approach to the treatment of PCOS with our investigational Ovarian Rebalancing Treatment. May Health, formerly AblaCare, is developing a modern approach to PCOS. Type: | 1 | 1 | 1 | 16 |
 | Kima Ventures We fund ambitious, cohesive teams with stellar learning and execution curves. Investing in 2 to 3 startups per week, all over the world. Type: | 44 | 34 | 1 | 19 |
 | Principles for Responsible Investment The UN-supported Principles for Responsible Investment, the world’s leading proponent of responsible investment. The Principles for Responsible Investment (PRI) is an investor initiative in partnership with UNEP FI and the UN Global Compact. Founded in 2006 and supported by the United Nations, the PRI has become the leading network for investors demonstrating their commitment to responsible ownership and long-term, sustainable returns. Pension funds, insurance companies, sovereign/development funds, investment managers and service providers make up the PRI network. Our goal is to grow investor interest in environmental, social and corporate governance issues (ESG), share best practice and support signatory needs in … Type: | 9 | 8 | 1 | 314 |
 | Syncona Limited Building the next generation of healthcare companies Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders. We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of … Type: | 9 | 3 | 1 | 51 |
 | Adjuvant Capital Adjuvant Capital is the leading investment fund focused on public health. Adjuvant Capital is a life sciences investment firm focused on global health. We make $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Type: | 1 | 0 | 1 | 16 |
 | Moorfields Eye Hospital, London Moorfields is one of the world’s leading eye hospitals, providing expertise in clinical care, research and teaching and education. Our main focus is the treatment and care of NHS patients with a wide range of eye problems, from common complaints to rare conditions, which require treatments not available anywhere else in the UK. We have over 30 locations in and around London, which enables us to provide expert treatment closer to patients’ homes. We are also a postgraduate teaching centre and a national centre for ophthalmic research involving, with the UCL Institute of Ophthalmology, the largest ophthalmic research programme in … Type: | 2 | 1 | 1 | 1,682 |
 | Inotrem Control innate immunity Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases. Tags: FrenchTech120 Type: | 7 | 6 | 1 | 34 |
 | Amolyt Pharma Advancing peptides for the treatment of rare endocrine and related diseases Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, … Tags: FrenchTech2030 Type: | 9 | 8 | 1 | 61 |
 | Myricx Bio Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. Type: | 2 | 1 | 1 | 12 |
 | ProQR Therapeutics Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing Type: | 3 | 3 | 1 | 163 |
 | RefleXion Medical SCINTIX biology-guided radiotherapy is now FDA cleared. SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease. cancer care, radiation therapy, life sciences, medical devices, biotechnology, oncology, manufacturing, PET scanner, electrical engineering, product engineering, algorithms engineer, new product development, and software engineering Type: | 2 | 2 | 1 | 240 |
 | Tigem Telethon Institute of Genetics and Medicine TIGEM is a multidisciplinary research Institute devoted to the study of the mechanisms underlying rare genetic diseases and to the development of new therapies. The institute is one of the most important centers for fundamental life science research in Italy (https://www.tigem.it/). It is particularly renowned for its research on diseases such as lysosomal disorders, membrane trafficking defects, disorders of liver metabolism, and eye diseases. The unique funding environment of TIGEM forges important critical mass and facilitates opportunities to conduct both long-term and high-impact science that would otherwise be difficult to undertake. TIGEM is a … Type: | 1 | 1 | 1 | 299 |
 | Varenne Capital Partners Varenne Capital Partners is a Paris-based, process-driven, global investment manager whose purpose is to deliver superior long-term returns with the minimum necessary risk-taking. We strive to achieve this goal by employing proprietary research and combining complementary investment frameworks in a single strategy: Long Equity, Short Equity, Merger Arbitrage and Tail Risk Hedging. Our ‘brokers are not welcome’ policy means that we rely exclusively on our own internal research and base our analysis on facts and figures. All of our investment frameworks stem from years of research and development and as a result comprise original methodologies, formalized processes, dedicated teams of … Type: | 5 | 2 | 1 | 38 |
 | Sixth Street Global investors developing themes and offering solutions to companies across all stages of growth Sixth Street is a global investment firm with over $75 billion in assets under management and committed capital. We use our long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street is dedicated to cross-platform collaboration at scale. We have more than 550 team members including over 200 investment professionals operating across our global locations. We invest through our diversified, collaborative investment platforms: TAO, Growth, Direct Lending, Strategic Capital, Fundamental Strategies, Infrastructure, … Type: | 4 | 3 | 1 | 693 |
 | Marks & Clerk Leading global network of intellectual property specialists We’re true specialists – focusing on IP and IP alone. With patent attorneys, trade mark attorneys, commercial lawyers and IP litigators, we can provide every type of intellectual property service you need. Our expertise is globally acknowledged - in our top tier status, the awards we’ve won and in the cutting-edge work we do, which helps shape future law. Intellectual property, Litigation, Prosecution, Patents, Trade Marks, and Law | 3 | 1 | 1 | 587 |
 | Mosaic TX An oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients. ABOUT US Mosaic Therapeutics is an oncology therapeutics company using advanced computational methods and next-generation cancer models to discover and develop novel targeted therapies. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programmes across a variety … Type: | 2 | 1 | 1 | 31 |
 | BrightHeart Advancing prenatal ultrasound screening with AI At BrightHeart, we believe every single fetal ultrasound screening exam should be performed with the highest level of accuracy, so each mother and baby receive the highest possible quality of care. Type: | 2 | 2 | 1 | 12 |
 | MoonLake Immunotherapeutics (NASDAQ: MLTX) Creating next-level therapies for inflammatory skin and joint diseases with Nanobody® science MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. Immunotherapy, inflammatory skin & joint diseases, partnering, IL17A / F, #MLTX, #Nanobody, #HS, #PsA, and #IL17 | 2 | 1 | 1 | 60 |
 | Womed This is a women's world Womed is pioneering innovative, safe and effective treatments to free women from challenging uterine pathologies: infertility, uterine bleeding, endometriosis. Type: | 10 | 1 | 1 | 12 |
 | AstronauTx AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease. Type: | 2 | 0 | 1 | 11 |
 | Qorium Real Leather, Reinvented Leather is loved. Leather is luxury. Leather is everywhere. Unfortunately, making leather is also polluting, challenging and controversial. Qorium creates beautiful, premium, and authentic leather without compromise. Cutting-edge science empowers us to dramatically reduce the vast impacts of today’s leather industry without quality reductions. By removing the cow from leather production, Qorium’s material has minimal climate impacts, low water and chemical usage, no land use, and no animal impacts. Simply put, Qorium reinvents leather. Better product. Better planet. Biotechnology, Cell cultured leather, Leather, Cell grown Leather, Sustainable Leather, and Animal free Leather Type: | 1 | 0 | 1 | 16 |
 | La Course des Lumières [Automatic translation follows] Together, let's light up the night against illness and for all sick people! Created in 2010, the Race of Lights is a national awareness event around the fight against disease. Since its creation, more than a million euros have been collected for the benefit of health organizations (foundations, hospitals, patient associations, etc.). Accessible to all, the event brings together more than 15,000 participants and 200 companies each year. Each participant, runner or walker, symbolically carries a luminous object to “light the night against illness and for all sick people”. solidarity, sport, running, walking, and team-building Type: | 5 | 5 | 1 | 1 |
 | Mainstay Medical First and Only FDA Approved Restorative Therapy for Chronic Mechanical Low Back Pain Mainstay Medical, led by a team of dedicated scientists, executives, engineers, and clinical experts, brings to you ReActiv8®, the first and only FDA-approved restorative treatment for mechanical chronic low back pain. RESTORE Control RESTORE Function RESTORE Stability ReActiv8 LIFE The Company was incorporated in Dublin, Ireland and headquartered in San Diego, CA. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands. Type: | 1 | 0 | 1 | 126 |
 | Turbine We are building the world’s first first predictive simulation of patient biology. Truly meaningful medicine comes from breakthroughs?in deeply understanding patient biology. We are building the world’s first first predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects. Drug Discovery, Biotechnology, Artificial Intelligence, in silico, Cell Biology, Simulated Experiments, Bioinformatics, and Pharmaceuticals Type: | 2 | 0 | 2 | 90 |
 | Mauna Kea Technologies The real-time in vivo cellular imaging platform that revolutionizes the way physicians diagnose and treat patients. Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative … Type: | 3 | 1 | 2 | 121 |
 | IRB Barcelona International research centre devoted to offer biomedical solutions for #cancer and other diseases linked to #aging. IRB Barcelona’s research purpose is to address fundamental biological questions in order to provide groundbreaking solutions to unmet medical needs. Our institute is organised around three major research challenges: Cancer Science, Aging and Metabolism, and Mechanisms of Disease, with the aim to decipher why diseases develop and find new ways to diagnose, prevent and treat them. Approximately 400 scientists, technical and administrative staff from 29 countries currently work at IRB Barcelona. IRB Barcelona's ultimate objective is to translate research results to the clinic and … Type: | 3 | 2 | 2 | 466 |
 | Abingworth Life Science Investing Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022. Investing in … Type: | 5 | 3 | 2 | 42 |
 | NatureWorks A naturally advanced biomaterials company using plants to turn greenhouse gases into IngeoTM️ PLA biopolymers. NatureWorks is an advanced materials company offering a broad portfolio of renewably-sourced polymers and chemicals to the packaging, polymers, fibers, and chemicals markets. With performance and economics that compete with oil-based plastics and fibers, naturally advanced IngeoTM polymers are valued for their unique functional properties and used in products from coffee capsules and electronics to diapers and wipes. Creating performance through chemistry, VercetTM lactide-based solutions help innovators realize significant, measurable performance and cost advantages in products such as C.A.S.E., toners, and surfactants. NatureWorks is jointly … Type: | 10 | 1 | 2 | 210 |
 | Gilde Healthcare Specialized healthcare investor in both Healthcare Venture & Growth as well as Healthcare Private Equity, managing €2.5B Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde Healthcare's lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare's venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are … Type: | 5 | 3 | 2 | 62 |
 | BT Group We’re one of the world’s leading communications services companies. At BT Group, the solutions we sell are integral to modern life. Our purpose is as simple as it is ambitious: we connect for good. There are no limits to what people can do when they connect. And as technology changes our world, connections are becoming even more important to everyday life. Today, that’s truer than ever. The connections we make are helping solve the world’s biggest challenges such as the global pandemic, climate change and cyber security. Through the power of technology, we’re supporting customers to live, work and play … Type: | 15 | 11 | 2 | 80,389 |
 | EnginZyme Developing technologies to meet the sustainability goals of the future Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the … Type: | 2 | 0 | 2 | 59 |
 | Phytolon Natural Food Colors Phytolon offers natural food colors, uniquely positioned to comply with the consumers needs for healthy food, and with the industry requirements for cost-efficiency and high quality. Phytolon leverages a novel and sustainable fermentation-based technology by which betalain natural colors are produced in baker's yeast. food colors, natural ingredients, yeast, fermentation, sustainability, biotechnology, and foodtech Type: | 2 | 0 | 2 | 27 |
 | BIOWEG Revolutionizing the Future of Bio-ingredients BIOWEG, founded in 2019 in Germany, is a purpose-driven organization powered by conscious ChemDesign. We match Bio-innovation to business problems. We explore and combine biotechnology, material science, and molecular simulation learning to create advanced sustainable bio-based high-performance ingredients. Our ingredients are 100% animal free, globally scalable, and sustainably produced without harsh chemicals. We work with results-oriented, forward-thinking companies, and consumer brands with global scale in the cosmetics, personal care, nutraceuticals, agricultural coatings, and food/beverage sectors who desire highly differentiated and sustainable science-based ingredient technologies. Material Science, Fermentation , Green Chemistry, Alternative Ingredients, Biobased Materials, Biodegradabe, … Type: | 22 | 3 | 2 | 20 |
 | Intermediate Capital Group (ICG) Global alternative asset manager, creating sustainable value by partnering with ambitious businesses. We are a global alternative asset manager with a track record of over 30 years. We are driven by purpose and sustainable results. We deliver outstanding investment performance to our clients, provide wide‐ranging capital solutions for corporates and owners of real assets, and create value for stakeholders, shareholders and communities. Private Markets, Private Capital, Alternative Asset Management, Private Credit, Private Debt, Secondaries, Structured Products, Real Assets, Infrastructure, Real Estate, and Life Sciences Type: | 6 | 1 | 2 | 739 |
 | Home Biosciences A new breed of biotech company A new breed of biotech company aiming to unlock scientific breakthrough by leveraging an asset-centric operating model Type: | 5 | 4 | 2 | 9 |
 | Citeline Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. Type: | 12 | 10 | 2 | 420 |
 | centdegrés Creative Activists Since 1988 We believe in bold creativity. For thirty years, we’ve focused all our energies on helping our clients win their battles, improve their impact, and challenge the status quo. Through design. We hunt down the best conditions for your projects in order to create unique personalised design and make a new kind of impact. Anything that will only achieve a partial result is a waste of time. We live by the certainty that there is no such thing as “hype”, freedom and creativity are crucial aspects of our approach. We have continuously created exceptional experiences, brands, products … | 2 | 2 | 2 | 62 |
 | Nuage Therapeutics We develop new selective and potent drugs for intrinsically disordered targets. Nuage Therapeutics is a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. Nuage Therapeutics mission is to leverage biomolecular condensation and chemical biology to develop selective inhibitors of intrinsically disordered proteins involved in challenging indications representing unmet medical needs. Type: | 4 | 1 | 2 | 21 |
 | ImmuONE Specialised translational approaches and in vitro testing services ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results. ImmuONE is partnered with the industry and academia to develop sustainable technologies for the future to support human-relevant, mechanistic driven safety assessments and develop animal product-free cell models. We offer a range of standard and bespoke assessments for inhalation safety assessment needs. ImmuONE provides innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, inflammation and can tailor to your inhalation safety assessment needs. … Type: | 4 | 0 | 2 | 17 |
 | ISALT [Automatic translation follows] Financing the new French industry and meeting the challenge of transitions “Our objective is to help French companies grow through long-term investment” ISALT is a portfolio management company whose mission is to invest long-term in the capital of listed or unlisted French companies. Since its creation in 2020, ISALT has set itself the ambition of developing a long-term investment platform with the aim of providing stable and constructive capital to French companies operating in key sectors for our economy. As such, it implements an investment strategy which consists of taking significant, long-term stakes in the capital of … Type: | 7 | 5 | 2 | 20 |
 | Cardiologs AI Serving Cardiology Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence. Machine Learning, Big Data, MedTech, Cardiology, Artificial Intelligence, ECG analysis, Holter analysis, and SaaS Type: | 14 | 9 | 3 | 88 |
 | Triple Ring Technologies A trusted partner in bringing technology to life. Triple Ring Technologies is a co-development company headquartered in Silicon Valley, with offices in Boston, Toronto, and Copenhagen. We partner with clients in medtech, life sciences, and sustainability & the environment to create new technologies, launch innovative projects, and start new ventures. Our capabilities span early R&D, product development, manufacturing, regulatory approval, market access, strategic investment, and incubation. For more information, please visit www.tripleringtech.com. For inquiries, please email info@tripleringtech.com. Advanced Research & Development - applied to commercial problems, Innovation Programs, Medical Device Design, Prototyping, Modeling, Validation, Product Development / Design, Grant Funded … Type: | 3 | 0 | 3 | 102 |
 | Talas Partners [Automatic translation follows] The right financing at the right time! Talas Partners is your partner of excellence to propel your company's innovation towards new horizons. Who are we ? Much more than a simple innovation financing consultancy firm, we become your partner to achieve your entrepreneurial objectives and lead you towards success. Our passion is to transform each innovative project into a successful entrepreneurial success. Our mission We have a clear mission: to help Startups and SMEs develop their businesses by mobilizing public or private financing. Our Support Present in the innovation ecosystem for a very long time, we guide … Type: | 4 | 1 | 3 | 3 |
 | Index Ventures Index helps the most ambitious entrepreneurs turn bold ideas into global businesses. Index Ventures partners with exceptional entrepreneurs – those with unique insight who are intrinsically driven to make their vision a reality. We help them turn their bold ideas into global businesses, and through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale up journey, we forge deep and long-lasting relationships with founders and their … | 11 | 7 | 3 | 114 |
 | NHS The NHS was launched in 1948. It was born out of a long-held ideal that good healthcare should be available to all, regardless of wealth – one of the NHS's core principles. With the exception of some charges, such as prescriptions, optical services and dental services, the NHS in England remains free at the point of use for all UK residents. This currently stands at more than 64.6 million people in the UK and 54.3 million people in England alone. The NHS in England deals with over 1 million patients every 36 hours. It covers everything, including antenatal screening, routine … Type: | 19 | 5 | 3 | 243,493 |
 | Crescendo Biologics Limited Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical … Type: | 4 | 2 | 3 | 63 |
 | Atlas Venture We build breakthrough biotech companies with remarkable life science entrepreneurs. Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. Biotech and Venture Capital Type: | 5 | 2 | 3 | 132 |
 | Marsh We help our clients and colleagues grow — and our communities thrive — by protecting and promoting Possibility. We help our clients and colleagues grow — and our communities thrive — by protecting and promoting Possibility. We seek better ways to manage risk and define more effective paths to the right outcome. We go beyond risk to rewards for our clients, our company, our colleagues, and the communities in which we serve. Marsh is the world’s leading insurance broker and risk advisor. With over 45,000 colleagues operating in 130 countries, Marsh serves commercial and individual clients with data-driven risk solutions … Type: | 10 | 7 | 3 | 12 |
 | BIOTECHFINANCES [Automatic translation follows] 1st weekly specialist information, biotech, medtech, e-health, finance published by Jacques Bernard Taste PRESENTATION The weekly Biotech Finances letter approaches from an economic and financial angle all questions linked to the development of the biotechnology sector and more broadly life sciences. Our target readership is mainly composed of biotechnology companies focused on health and the development of new therapies and new treatments for diseases, pharmaceutical companies (big pharma and other laboratories), investors, business angels, funds investments, venture capital, specialists in the biotech sector, institutional investors, legal advisors, development experts, and service providers and equipment suppliers. Our articles … Type: | 13 | 4 | 3 | 9 |
 | TAC ECONOMICS An independent European research group providing advisory services on international economic and financial issues TAC ECONOMICS is a French independent leading provider of economic and financial consulting services with a strong expertise on country risk based on AI and data-driven solutions. Our team of experienced economists and data scientists specializes in providing cutting-edge data, models, and analysis to help our clients detect major risks and evaluate investment opportunities. Our commitment to AI and data-driven solutions is rooted in our pioneering work in the early 1990s, where we developed artificial intelligence tools to predict financial crises in emerging economies and prevent … | 6 | 1 | 3 | 12 |
 | Protera Smarter proteins for a sustainable future. By 2050, the world's population will surpass 10 billion people. To feed the current population and future generations we need to address global food challenges, today. How can we solve this problem without overwhelming the planet? And how can we deliver higher quality, more nutritious food for everyone? With Protera’s Natural IntelligenceTM technology, we believe the future is already here. Protera’s technology uses predictive algorithms that calculate millions of amino acid combinations and simulate protein patterns in a matter of seconds. Our technology is based in Deep Learning and allows us to shine a … Type: | 3 | 0 | 3 | 41 |
 | Numbered We are a design and technology agency crafting beautiful digital experiences and products Contact@numbered.com Numbered is an awards winning creative agency working with fashion, tech & lifestyle brands. We collaborate closely with our clients to tell their stories, engaging audiences by building beautiful experiences & products. Based in Amsterdam & New-york. We strongly believe every brand and project is unique and should be tailor-made from industry leaders to early stage companies. We don’t do one size fits all. Collaborating with international brands, founders, start-ups, venture capitals, and more – producing, results-driven, unique products and experiences from conception to delivery. With … Type: | 3 | 0 | 3 | 37 |
 | Phacilitate Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences Type: | 4 | 1 | 3 | 18 |
 | Mintz Built on excellence. Driven by change. Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. is a general practice, full-service Am Law 100 law firm employing approximately 600+ attorneys serving clients worldwide. We are headquartered at One Financial Center in Boston’s Financial District and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, Washington, DC, and an office in Toronto, Canada. Mintz was founded in 1933 by Haskell Cohn and Benjamin Levin. The firm’s Managing Member is Robert I. Bodian. Our collaborative attorneys work within four core practice areas — Transactional, Intellectual Property, Litigation & … Type: | 8 | 2 | 3 | 1,328 |
 | Cancer Campus [Automatic translation follows] Cancer Campus is a research and innovation park developing in Villejuif (Val-de-Marne) Cancer Campus is a research and innovation park developing in Villejuif (Val-de-Marne), around Gustave Roussy, the first cancer center in Europe. Its objective is to bring together all the talents (health professionals, researchers, students, businesses) and citizens concerned by the disease to become an international reference site in innovation in health and oncology. In this context, we are developing 3 programs dedicated to promoting entrepreneurship in oncology: - the Oncoentrepreneur program: tailor-made training and support set up for start-up projects in biotech, medtech and e-health. … Type: | 5 | 1 | 3 | 3 |
 | Parc Científic de Barcelona [Automatic translation follows] Where Science becomes Business Located in the knowledge campus, the PCB provides you with basic ordinary services and a privileged environment for networking. More than 2,700 highly qualified researchers work at the PCB; join our community! | 5 | 2 | 3 | 107 |
 | GFBiochemicals GFBiochemicals is on a mission to create a more sustainable future and transform the chemicals industry GFBiochemicals is a biochemical company that specializes in the research, development, production and business development of bio-based and renewable chemicals. We provide high-quality, bio-based chemicals to businesses across the world. Our focus is green chemistry – a sustainable alternative to traditional oil-based chemistry. Our technology is proprietary and has been developed in-house over many years. GFBiochemicals is headquartered in Paris, France and has subsidiaries in Geleen, the Netherlands and Minneapolis, USA. GFBiochemicals acquired Segetis, in 2016, as part of our growth strategy to integrate … Type: | 5 | 2 | 3 | 33 |
 | Sitryx Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at … Type: | 3 | 2 | 3 | 51 |
 | Italian Tech Alliance [Automatic translation follows] Formerly VC Hub Italia, it is the association of Venture Capital, investors in innovation, startups and innovative SMEs Italian Tech Alliance is the reference association for: - venture capital funds; - investors in innovation; - innovative startups and SMEs. The objective of the association is to promote the development of the technology and innovation ecosystem in Italy, working closely with institutions. The contents of the Italian Tech Alliance disseminate news, opportunities and interesting reports for private and public stakeholders who work for the economic and social growth of the country. The following currently sit on the Board … Type: | 7 | 3 | 3 | 15 |
 | Bioptimus We build foundation models that will transform biology. We use cutting-edge technology to transform multiscale data into actionable representations to fuel breakthrough discoveries. Join us on our mission to build foundation models that transform biology. artificial intelligence, biology, and foundation models Type: | 4 | 2 | 3 | 13 |
 | Forbion Impacting the future of medicine Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. … Type: | 6 | 4 | 3 | 60 |
 | Pyrowave Electrifying progress. We are leading the revolution in #sustainable #greenchemistry by offering a modular microwave based technology that can #unzip waste plastics back to their root chemical form. Styrene, Polyolefin wax, Lubricants, Microwave, Plastics, #CircularEconomy, #LowCarbonCement , CleanTechnology, #Nanorecycling, GreenSolutions, and #WasteReduction Type: | 5 | 1 | 4 | 15 |
 | Motive Partners Investors, Operators, Innovators Motive Partners is a private equity firm with offices in New York City and London, focusing on growth equity and buyout investments in software and information services companies based in North America and Europe and serving five primary subsectors: Banking & Payments, Capital Markets, Data & Analytics, Investment Management and Insurance. Motive Partners brings differentiated expertise, connectivity and capabilities to create long-term value in financial technology companies. More information on Motive Partners can be found at www.motivepartners.com Type: | 11 | 2 | 4 | 117 |
 | Linklaters Linklaters is a leading global law firm, supporting and investing in the future of our clients wherever they do business. We combine legal expertise with a collaborative and innovative approach to help clients navigate constantly evolving markets and regulatory environments, pursuing opportunities and managing risk worldwide. http://www.linklaters.com Attorney Advertising: Prior results do not guarantee a similar outcome Type: | 16 | 10 | 4 | 6 |
Incubators & VCs